Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Yttrium 90-labelled edotreotide

Drug Profile

Yttrium 90-labelled edotreotide

Alternative Names: 90Y-SDZ-SMT-487; 90Y-DOTA-D-Phe1-Tyr3-octreotide; 90Y-SMT 487; OctreoTher™; Onalta; SMT-487; Y-90 SMT-487; Y-90-DOTA-tyr3-Octreotide; Yttrium 90 labelled endotreotide; Yttrium 90 labelled SMT 487

Latest Information Update: 11 Dec 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Molecular Insight Pharmaceuticals; University of Iowa
  • Class Antineoplastics; Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours

Most Recent Events

  • 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals
  • 06 Aug 2010 Yttrium 90-labelled edotreotide is still in phase II trials for Neuroendocrine tumours in USA
  • 04 Sep 2009 Yttrium 90-labelled edotreotide sub-licensed to BioMedica Life Sciences in specific countries in Europe, the Middle East, North Africa, Russia, and Turkey
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top